Circulating tumour-derived DNA as a predictive biomarker to evaluate response to nivolumab treatment in patients with non-small cell lung cancer

Trial Profile

Circulating tumour-derived DNA as a predictive biomarker to evaluate response to nivolumab treatment in patients with non-small cell lung cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Nov 2017 New trial record
    • 24 Oct 2017 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top